Advertisement
Research
Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...
Cardio-Oncology 2017 3:5
Published on: 30 June 2017
Research
Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...
Cardio-Oncology 2017 3:4
Published on: 1 June 2017
Editorial
Cardio-Oncology 2017 3:3
Published on: 13 March 2017
Review
Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...
Cardio-Oncology 2017 3:2
Published on: 9 March 2017
Research
Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...
Cardio-Oncology 2017 3:1
Published on: 19 January 2017
Short communication
Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of ...
Cardio-Oncology 2016 2:9
Published on: 15 November 2016
Short communication
The treatment of Acute Myeloid Leukemia (AML) leads to several functional limitations. Especially cardiac burden following cardiotoxic chemotherapy, which limits exercise and competitive sport in the long-term...
Cardio-Oncology 2016 2:8
Published on: 14 October 2016
Research
The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in canc...
Cardio-Oncology 2016 2:7
Published on: 6 October 2016
Research
Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...
Cardio-Oncology 2016 2:6
Published on: 14 July 2016
Review
The diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurs...
Cardio-Oncology 2016 2:5
Published on: 19 April 2016
Review
The vascular endothelium plays a fundamental role in the maintenance of tissue homeostasis, regulating local blood flow and other physiological processes. Chemotherapeutic drugs and target therapies, including...
Cardio-Oncology 2016 2:3
Published on: 15 March 2016
Research
Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...
Cardio-Oncology 2016 2:4
Published on: 15 March 2016
Review
The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...
Cardio-Oncology 2016 2:2
Published on: 3 March 2016
Review
Advances in breast cancer treatment have improved disease-free survival and overall survival in women with early-stage breast cancer. However, these improvements may be attenuated by the adverse cardiovascular...
Cardio-Oncology 2016 2:1
Published on: 25 February 2016
Review
New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...
Cardio-Oncology 2015 1:6
Published on: 7 December 2015
Review
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improvi...
Cardio-Oncology 2015 1:5
Published on: 4 December 2015
Research
Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...
Cardio-Oncology 2015 1:1
Published on: 26 November 2015
Review
Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the ...
Cardio-Oncology 2015 1:3
Published on: 26 November 2015
Editorial
Cardio-Oncology 2015 1:2
Published on: 26 November 2015
Review
Exposure to high doses of ionizing radiation is associated with damage to the heart and coronary arteries. However, only recently have studies with high-quality individual dosimetry data allowed this risk to b...
Cardio-Oncology 2015 1:4
Published on: 26 November 2015
